You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
|
|---|---|
| Published in |
Lancet Oncology, October 2009
|
| DOI | 10.1016/s1470-2045(09)70284-0 |
| Pubmed ID | |
| Authors |
S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp, for the Eastern Cooperative Oncology Group |
X Demographics
The data shown below were collected from the profiles of 942 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 293 | 31% |
| United States | 113 | 12% |
| United Kingdom | 23 | 2% |
| Canada | 11 | 1% |
| Australia | 11 | 1% |
| Spain | 6 | <1% |
| Germany | 5 | <1% |
| Turkey | 4 | <1% |
| Japan | 4 | <1% |
| Other | 57 | 6% |
| Unknown | 415 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 769 | 82% |
| Scientists | 88 | 9% |
| Practitioners (doctors, other healthcare professionals) | 65 | 7% |
| Science communicators (journalists, bloggers, editors) | 20 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 415 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| France | 1 | <1% |
| Italy | 1 | <1% |
| Brazil | 1 | <1% |
| Spain | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 407 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 67 | 16% |
| Other | 60 | 14% |
| Student > Ph. D. Student | 47 | 11% |
| Student > Bachelor | 38 | 9% |
| Student > Master | 35 | 8% |
| Other | 89 | 21% |
| Unknown | 79 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 213 | 51% |
| Agricultural and Biological Sciences | 28 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 5% |
| Biochemistry, Genetics and Molecular Biology | 18 | 4% |
| Nursing and Health Professions | 10 | 2% |
| Other | 34 | 8% |
| Unknown | 90 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 423. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2024.
All research outputs
#69,684
of 25,782,229 outputs
Outputs from Lancet Oncology
#81
of 6,939 outputs
Outputs of similar age
#100
of 108,742 outputs
Outputs of similar age from Lancet Oncology
#1
of 28 outputs
Altmetric has tracked 25,782,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,939 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,742 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.